基于生物信息学浅析芍麻止痉颗粒治疗抽动秽语综合征的作用机制

王嘉欢; 仲博; 王晓敏

PDF(3361 KB)

武警医学 ›› 2025, Vol. 36 ›› Issue (11) : 970-977.

论著

基于生物信息学浅析芍麻止痉颗粒治疗抽动秽语综合征的作用机制

王嘉欢¹, 仲博², 王晓敏³

作者信息 +

Bioinformatics-based analysis of the mechanism of Shaoma Zhijing granules in treating tourette syndrome

WANG Jiahuan¹, ZHONG Bo², WANG Xiaomin³.

Author information +

文章历史 +

摘要

目的采用生物信息学分析手段探讨芍麻止痉颗粒(SMZJG)治疗抽动秽语综合征(TS)的作用机制。方法结合生物信息学和分子对接技术筛选活性化合物和候选靶点,进行通路富集分析,以解释SMZJG对TS的作用机制。结果生物信息学分析筛选得到92个关键靶点,提示这些靶点在SMZJG治疗TS中可能发挥重要作用。GO功能分析表明,SMZJG对TS的治疗效果可能与突触传递、神经元突触可塑性调节有关。KEGG分析得到神经活性配体-受体相互作用、cAMP信号通路、钙信号通路等多条信号通路。最后以其中8个潜在活性成分与相对应的TS相关靶点进行分子对接,发现天麻素、芍药苷、钩藤碱等多个成分均表现出较好的亲和力,表明其与TS已知靶标有直接作用关系。结论 SMZJG可基于其药理特性,通过多成分协同作用,多靶点及多通路间的复杂网络调控机制,发挥治疗TS的作用。

Abstract

Objective To explore the mechanism of Shaoma Zhijing granules (SMZJG) in treating tourette syndrome (TS) by using bioinformatics analysis methods. Methods Bioinformatics and molecular docking techniques were integrated to screen the active compounds and candidate targets, and the pathway enrichment analysis was performed to explain the mechanism of SMZJG against TS. Results A total of 92 pivotal targets were screened by bioinformatics analysis, suggesting their potential role in SMZJG’s therapeutic effect on TS. GO function analysis revealed that the therapeutic effect of SMZJG on TS was possibly associated with synaptic transmission and regulation of neuronal synaptic plasticity. KEGG analysis obtained multiple signaling pathways such as neuroactive ligand-receptor interaction, cAMP signaling pathway, and calcium signaling pathway. Molecular docking was carried out with 8 main active ingredients with corresponding TS-related targets. It was found that several ingredients, such as gastrodin, paeoniflorin and rhynchophylline, showed good affinity, suggesting a direct-action relationship with the known targets of TS. Conclusions Based on its pharmacological characteristics, SMZJG can exert a therapeutic effect on TS through the synergistic effect of multiple components and a complex network of interaction mechanisms among multi-targets and pathways.

导出引用

王嘉欢, 仲博, 王晓敏. 基于生物信息学浅析芍麻止痉颗粒治疗抽动秽语综合征的作用机制[J]. 武警医学. 2025, 36(11): 970-977

WANG Jiahuan, ZHONG Bo, WANG Xiaomin.. Bioinformatics-based analysis of the mechanism of Shaoma Zhijing granules in treating tourette syndrome[J]. Medical Journal of the Chinese People Armed Police Forces. 2025, 36(11): 970-977

中图分类号： R96

参考文献

[1] Set K K, Warner J N. Tourette syndrome in children: an update[J]. Curr Probl Pediatr Adolesc Health Care, 2021, 51(7):101032.
[2] Robertson N P. Advances in Tourette’s syndrome[J]. J Neurol, 2023, 270(3): 1808-1810.
[3] Frey J, Malaty I A. Tourette syndrome treatment updates: a review and discussion of the current and upcoming literature[J]. Curr Neurol Neurosci Rep, 2022, 22(2): 123-142.
[4] Jimenez-Shahed J. Medical and surgical treatments of Tourette syndrome[J]. Neurol Clin, 2020, 38(2): 349-366.
[5] Johnson K A, Worbe Y, Foote K D, et al. Tourette syndrome: clinical features, pathophysiology, and treatment[J]. Lancet Neurol, 2023, 22(2): 147-158.
[6] 刘晓玲,段彦彦,陶兴茹,等.儿童医院中成药使用现状和建议[J].中成药, 2019, 41(7): 1753-1756.
[7] Lai W Y, Wei C C, Lin C H, et al. Integrative traditional Chinese medicine treatment for children with obstructive sleep apnea[J]. J Tradit Complement Med, 2024, 14(1): 109-120.
[8] 王永炎,王蕾,王忠,等.中医药对儿童抽动症防治刍议[J]. 中国中西医结合杂志, 2022, 42(2): 148-150.
[9] 古欣,岑丽婷,李嫦红.芍麻止痉颗粒联合耳穴压豆对小儿抽动障碍症状改善及微量元素水平的影响[J].中国药业, 2024, 33(15): 81-84.
[10] 吴雪, 万楚川, 张宇轩,等. 芍麻止痉颗粒治疗儿童抽动障碍的药物经济学评价[J]. 中国中药杂志, 2024, 49(15): 4238-4248.
[11] 刘国珍,廖金花,邹淑芹, 等.芍麻止痉颗粒治疗儿童抽动症的临床研究[J].中华中医药学刊, 2024, 42(6): 121-124.
[12] 吴雪,王忠,廖星,等.3种口服中成药治疗儿童抽动障碍的快速卫生技术评估[J].中国中药杂志, 2023, 48(14): 3965-3976.
[13] Kong X, Liu C, Zhang Z, et al. BATMAN-TCM 2.0: an enhanced integrative database for known and predicted interactions between traditional Chinese medicine ingredients and target proteins[J]. Nucleic Acids Res, 2024, 52(D1): D1110-D1120.
[14] 魏婷婷, 沈晨, 韩园园, 等. UPLC-Q-TOF-MS快速鉴定止动颗粒血浆及尿液中移行成分[J]. 中草药, 2019, 50(17): 4244-4253.
[15] Zhou Y, Zhang Y, Zhao D, et al. TTD: Therapeutic Target Database describing target druggability information[J]. Nucleic Acids Res, 2024, 52(D1): D1465-D1477.
[16] Amberger J S, Hamosh A. Searching Online Mendelian Inheritance in Man(OMIM): a knowledgebase of human genes and genetic phenotypes[J]. Curr Protoc Bioinformatics, 2017, 58:1.2.1-1.2.12.
[17] Pinero J, Ramirez-Anguita J M, Sauch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update[J]. Nucleic Acids Res, 2020, 48(D1): D845-D855.
[18] Knox C, Wilson M, Klinger C M, et al. DrugBank 6.0: the DrugBank knowledgebase for 2024[J]. Nucleic Acids Res, 2024, 52(D1): D1265-D1275.
[19] Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses[J]. Curr Protoc Bioinformatics, 2016, 54: 1301-1303.
[20] UniProt C. UniProt: the universal protein knowledgebase in 2023[J]. Nucleic Acids Res, 2023, 51(D1): D523-D531.
[21] Sun L, Dong S, Ge Y, et al. DiVenn: an interactive and integrated web-based visualization tool for comparing gene lists[J]. Front Genet, 2019, 10: 421.
[22] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Res, 2003, 13(11): 2498-2504.
[23] Sherman B T, Hao M, Qiu J, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists(2021 update)[J]. Nucleic Acids Res, 2022, 50(W1): W216-W221.
[24] Eberhardt J, Santos-Martins D, Tillack A F, et al. AutoDock vina 1.2.0: new docking methods, expanded force field, and python bindings[J]. J Chem Inf Model, 2021, 61(8): 3891-3898.
[25] Trott O, Olson A J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading[J]. J Comput Chem, 2010, 31(2): 455-461.
[26] Chou C Y, Agin-Liebes J, Kuo S H. Emerging therapies and recent advances for Tourette syndrome[J]. Heliyon, 2023, 9(1): e12874.
[27] Qi H, Liu R, Zheng W, et al. Efficacy and safety of traditional Chinese medicine for Tourette's syndrome: a Meta-analysis of randomized controlled trials[J]. Asian J Psychiatr, 2020, 47: 101853.
[28] Hong H, Lu X, Wu C, et al. A review for the pharmacological effects of paeoniflorin in the nervous system[J]. Front Pharmacol, 2022, 13: 898955.
[29] 树鸣霞, 晁鹏一, 孟庆军. 阿立哌唑联合天麻治疗抽动障碍[J]. 中国生化药物杂志, 2010, 31(1): 55-56.
[30] Zhao Q, Hu Y, Yan Y, et al. The effects of Shaoma Zhijing granules and its main components on Tourette syndrome[J]. Phytomedicine, 2024, 129: 155686.
[31] Liu Y, Gao J, Peng M, et al. A review on central nervous system effects of gastrodin[J]. Front Pharmacol, 2018, 9: 24.
[32] Xiao G, Tang R, Yang N, et al. Review on pharmacological effects of gastrodin[J]. Arch Pharm Res, 2023, 46(9-10): 744-770.
[33] Wang Y, Zhao L, Li A Y. Gastrodin-a potential drug used for the treatment of Tourette syndrome[J]. J Pharmacol Sci, 2021, 145(3): 289-295.
[34] Wang X L, Feng S T, Wang Y T, et al. Paeoniflorin: a neuroprotective monoterpenoid glycoside with promising anti-depressive properties[J]. Phytomedicine, 2021, 90: 153669.
[35] Hongyan L, Mengjiao Z, Chunyan W, et al. Rhynchophyllin attenuates neuroinflammation in Tourette syndrome rats via JAK2/STAT3 and NF-kappaB pathways[J]. Environ Toxicol, 2019, 34(10): 1114-1120.
[36] Long H, Ruan J, Zhang M, et al. Rhynchophylline attenuates tourette syndrome via BDNF/NF-kappaB pathway in vivo and in vitro[J]. Neurotox Res, 2019, 36(4): 756-763.
[37] Hongyan L, Mengjiao Z, Chunyan W, et al. Rhynchophylline attenuates neurotoxicity in tourette syndrome rats[J]. Neurotox Res, 2019, 36(4): 679-687.
[38] Yang J, Wu X, Yu H, et al. NMDA receptor-mediated neuroprotective effect of the scutellaria baicalensis georgi extract on the excitotoxic neuronal cell death in primary rat cortical cell cultures[J]. Sci World J, 2014, 2014: 459549.
[39] Barnes G N, Slevin J T. Ionotropic glutamate receptor biology: effect on synaptic connectivity and function in neurological disease[J]. Curr Med Chem, 2003, 10(20): 2059-2072.
[40] Burre J, Sharma M, Sudhof T C. Cell biology and pathophysiology of alpha-Synuclein[J]. Cold Spring Harb Perspect Med, 2018, 8(3): a024091.
[41] Hsu C J, Wong L C, Lee W T. Immunological dysfunction in Tourette syndrome and related disorders[J]. Int J Mol Sci, 2021, 22(2): 853-868.
[42] Li Y, Wang X, Yang H, et al. Profiles of proinflammatory cytokines and T cells in patients with Tourette syndrome: a Meta-analysis[J]. Front Immunol, 2022, 13: 843247.
[43] Mestre T A, Zurowski M, Fox S H. 5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders[J]. Expert Opin Investig Drugs, 2013, 22(4): 411-421.
[44] Nunez A, Zegarra-Valdivia J, Fernandez de Sevilla D, et al. The neurobiology of insulin-like growth factor I: from neuroprotection to modulation of brain states[J]. Mol Psychiatry, 2023, 28(8): 3220-3230.
[45] Maezawa I, Zou B, Di Lucente J, et al. The anti-amyloid-beta and neuroprotective properties of a novel tricyclic pyrone molecule[J]. J Alzheimers Dis, 2017, 58(2): 559-574.
[46] Lin W D, Tsai F J, Chou I C. Current understanding of the genetics of tourette syndrome[J]. Biomed J, 2022, 45(2): 271-279.
[47] Su S Y, Hsieh C L, Wu S L, et al. Transcriptomic analysis of EGb 761-regulated neuroactive receptor pathway in vivo[J]. J Ethnopharmacol, 2009, 123(1): 68-73.
[48] Buse J, Schoenefeld K, Munchau A, et al. Neuromodulation in Tourette syndrome: dopamine and beyond[J]. Neurosci Biobehav Rev, 2013, 37(6): 1069-1084.
[49] Lauss M, Kriegner A, Vierlinger K, et al. Characterization of the drugged human genome[J]. Pharmacogenomics, 2007, 8(8): 1063-1073.
[50] Widomska J, De Witte W, Buitelaar J K, et al. Molecular landscape of Tourette's disorder[J]. Int J Mol Sci, 2023, 24(2): 1428.
[51] Singer H S, Hahn I H, Krowiak E, et al. Tourette's syndrome: a neurochemical analysis of postmortem cortical brain tissue[J]. Ann Neurol, 1990, 27(4): 443-446.
[52] Pourtavakoli A, Ghafouri-Fard S. Calcium signaling in neurodevelopment and pathophysiology of autism spectrum disorders[J]. Mol Biol Rep, 2022, 49(11): 10811-10823.